Archives

We are currently living in extraordinary times, but please rest assured we are doing all that we can to adapt to the situation, maintain safety among our employees and ensure our clients still [...]

Earlier this year Ashtons were consulted by the EU Exit Team, which is part of the Commercial Directorate of the Department of Health & Social Care (DHSC), regarding the preparations that we [...]

Cariprazine (Reagila) is a new second-generation antipsychotic which is licensed to treat schizophrenia in adults (over 18 years). It is only available as an oral capsule and is presented in [...]

The Food Standards Agency (FSA) has launched a publicity campaign to warn consumers about the health risks of using dietary products commonly known as ‘fat burners’ which are mainly obtained via [...]

What is the current risk of shortages for medicines and medical products due to Brexit? Should there be a no-deal Brexit, then there may be shortages of some medicines and other products due to [...]

A new formulation of clozapine will be available from June 2019 consisting of an oral dispersible tablet marketed as Zaponex orodispersible tablets by the company Leyden Delta BV. The special [...]

Buprenorphine has been long-established as an opioid substitution medication available as sublingual tablets. It is an opioid partial agonist/antagonist with strong receptor binding affinity and [...]

Lord Carter of Coles had led a review of NHS mental health and community health services to identify areas for improvement. These services account for about £17 billion of expenditure in England, [...]

Falsified medicines include counterfeit and unauthorised medicines and these can pose a health risk for patients. They are often disguised as authentic medicines and may be impossible to detect [...]

Prescriptions for Controlled Drugs (Schedule 2 and 3) can only be dispensed legally if the prescription contains all the mandatory requirements specified in the Misuse of Drugs Regulations 2001. [...]